Antiviral Combination

Antiviral Therapy for Pain and Fatigue

Dogwood is developing novel, proprietary, fixed dose combinations of anti-herpesvirus medications combined COX-2 inhibitors designed to synergistically suppress herpesvirus replication, with the end goal of reducing virally promoted disease symptoms.

Synergy
Our novel therapeutics IMC-1 and IMC-2 are directed at interrupting an ongoing immune and inflammatory response by suppressing reactivated herpesviruses. By suppressing the abnormal stress response, these drugs may alleviate the symptoms caused by Long COVID, Fibromyalgia, IBS, Chronic Fatigue and other somatic syndrome disorders. Studies have shown that neither antivirals nor COX-2/nonsteroidal anti-inflammatory drugs (“NSAIDS”) taken alone result in a meaningful clinical benefit. However, when administered in combination, a synergistic response has been observed in clinical studies.

Evidence of IMC-1’s efficacy on a broad spectrum of FM symptoms was previously demonstrated in a Phase 2a clinical trial. In this trial, IMC-1 delivered statistically significant reduction in FM related pain, fatigue, anxiety and depressive symptoms and improved overall patient health and functioning.

In an open-label, single-center, investigator-initiated study that was conducted at the Bateman Horne Center (“BHC”) with an unrestricted investigational grant, IMC-2 exhibited clinically and statistically significant improvements in fatigue, pain, and symptoms of autonomic dysfunction and general well-being related to Long-COVID when compared to a control cohort of female Long-COVID patients matched by age, gender and length of illness and treated with routine care. The mean duration of Long-COVID illness was two years for both the treated and control cohort prior to enrollment in this trial.